TherapeuticsMD Stock Bulls Get a Win with Imvexxy Approval

In the options pits, traders were selling to open TXMD calls

May 30, 2018 at 9:29 AM
facebook X logo linkedin


Women's health specialist TherapeuticsMD Inc (NASDAQ:TXMD) is seeing its stock rally today, up 4.5% at $6.72, thanks to news the Food and Drug Administration (FDA) approved its hormone therapy Imvexxy for the treatment of vulvar vaginal atrophy -- marking the company's first approved drug. As such, Cantor Fitzgerald -- which sent the stock soaring back in November -- reiterated its $26 price target and "overweight" rating.

Wall Street was already in love with TXMD, as all seven analysts in coverage have "strong buy" ratings on the shares, and the average 12-month price target is $14.44, more than double current levels. However, there are plenty of skeptics outside the analyst community, with almost one-third of the equity's float controlled by short sellers. This would suggest TherapeuticsMD stock could be a short squeeze candidate.

As for options data, call buying has been popular -- but so has call selling. Peak open interest sits at the June 7 call, and the June 5 and 6 strikes are also home to notable open interest, while data shows a mix of buy- and sell-to-open activity at each of these contracts. Meanwhile, the June 8 call saw a lot of buying activity in recent weeks.

Looking at the charts, the shares have been trending higher since late March, guided higher by their 20-day moving average and recently overtaking the 200-day moving average. Overall, TXMD was up almost 62% year-over-year even before today's pop.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI